China Alzheimer’s Disease Drugs Market Analysis

China Alzheimer’s Disease Drugs Market Executive Summary

The China Alzheimer’s Disease Drugs market was valued at $1.24 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 9.42% from 2022 to 2030 and will reach $2.64 Bn in 2030. Alzheimer's disease is a progressive brain condition. Changes in the brain that result in protein deposits are what define it. The brain shrinks as a result of Alzheimer's disease, and eventually, brain cells pass away. The most frequent cause of dementia, which is characterized by a slow loss of memory, thinking, behavior, and social abilities, is Alzheimer's disease. The ability to function is impacted by these modifications.

In recent decades of social and economic development, China's population has rapidly aged due to the proliferation of neurological illnesses, including Alzheimer's disease (AD) and related dementias (ADRD). In China, AD is now the fifth greatest cause of death for both urban and rural residents, and its incidence rate, morbidity, and mortality have all progressively climbed. This has resulted in greater financial burdens for individuals, families, and society as a whole. For this growing population with ADRD, the "Healthy China Action" plan of 2019–2030 encourages the shift from disease treatment to health maintenance. This paper analyses the economic impact of the disease summarises the status of clinical diagnosis and treatment, defines relevant epidemiological trends, and lists current public health resources that are accessible.

Market Dynamics

Market Growth Drivers

One of the primary drivers of the Alzheimer’s Disease drugs market is the rapidly aging China population. According to a report by the United Nations, the number of people aged 60 years and older is expected to double by 2050, reaching 2.1 billion. As the risk of Alzheimer’s disease increases with age, this demographic shift is expected to drive demand for Alzheimer’s Disease drugs. The number of people with Alzheimer’s Disease is expected to rise significantly in the coming years due to aging populations and lifestyle changes.

According to a report by the Alzheimer’s Disease Association, an estimated 6.2 Mn Americans aged 65 and older are living with Alzheimer’s Disease in 2021, and this number is projected to reach 12.7 Mn by 2050. This increasing prevalence is expected to drive the growth of the Alzheimer’s Disease drugs market. The development of new technologies is driving innovation in the Alzheimer’s Disease drugs market. For example, the emergence of biomarkers and the use of artificial intelligence in drug development are leading to more effective and efficient drug discovery and development. Governments and non-profit organizations around the world are increasing their efforts to raise awareness about Alzheimer’s Disease and to support research into new treatments. For example, the U.S. National Plan to Address Alzheimer’s Disease aims to prevent and effectively treat Alzheimer’s Disease by 2025, driving investment in research and development.

Market Restraints

The Chinese pharmaceutical industry is heavily regulated, and there are significant challenges associated with obtaining regulatory approval for new drugs. This can lead to delays in bringing new drugs to market and can increase the cost of drug development. The Chinese government has been working to control healthcare costs, which has led to pricing pressures in the pharmaceutical industry. This can limit the profitability of drugs, which can discourage investment in drug development.

China's population became older more quickly, and age-related disease incidence, morbidity, and mortality were all markedly elevated. The prevalence of Alzheimer's disease (AD) is rising, and its social and economic costs are getting worse, creating serious health and social issues that are endangering both urban and rural populations in China.  China has 15.07 Mn people with dementia, including 9.83 Mn people with AD, 3.92 Mn people with vascular dementia, and 1.32 Mn people with other types of dementia, according to a recent national cross-sectional survey conducted in 2020.

Competitive Landscape

Key Players

• Shanghai Green Valley Pharmaceutica
• Eisai Co.
• Eli Lilly and Company
• H. Lundbeck A/S
• Johnson and Johnson
• Hengrui Medicine Co
• Jiangsu Hengrui
• Novartis AG
• Chongqing Zhifei Biological Products
• Pfizer
• CSPC Pharmaceutical Group

Healthcare Policies and Regulatory Landscape

In 2013, China's government released a national Alzheimer's disease plan that aims to improve the prevention and treatment of Alzheimer's disease and other forms of dementia. The plan includes measures to improve public awareness of the disease, increase research funding, and improve the quality of care for people with the disease. China has also established a national dementia network to coordinate efforts to address the disease. The network includes healthcare providers, researchers, and patient organizations, and aims to improve early diagnosis and treatment of dementia.

Reimbursement Scenario

In China, reimbursement for healthcare services is primarily managed by the National Healthcare Security Administration (NHSA). The NHSA oversees the country's healthcare insurance system, which covers over 95% of the population. Under the healthcare insurance system, patients are reimbursed for a portion of their medical expenses. The amount of reimbursement depends on the type of insurance plan the patient has, as well as the specific medical services received. The NHSA divides medical services into categories based on their level of importance and necessity, and different reimbursement rates are applied to each category.

Additionally. the government health insurance programs in China include the Basic Medical Insurance (BMI) program, the New Rural Cooperative Medical Scheme (NRCMS), and the Urban Resident Basic Medical Insurance (URBMI) program. These programs provide varying levels of reimbursement for drugs, with BMI generally providing the highest level of coverage.